RnRMarketResearch.com adds “Keratitis – Pipeline Review, H1 2015” to its store. The report provides an overview of the Keratitis’s therapeutic pipeline.
DALLAS, June 4, 2015 /PRNewswire-iReach/ — The report “Keratitis – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Keratitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Keratitis with 24 market data tables and 14 figures, spread across 70 pages is available at http://www.rnrmarketresearch.com/keratitis-pipeline-review-h1-2015-market-report.html.
Logo – http://photos.prnewswire.com/prnh/20150604/220811
Keratitis is an inflammation or irritation of the cornea. Keratitis has many causes, including infection, dry eyes, physical and chemical injury, and underlying medical diseases. The most common infectious cause is herpes simplex virus type 1, but it can also be due to varicella zoster. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Keratitis – Pipeline Review, H1 2015 report include: Adamis Pharmaceuticals Corporation, Cellceutix Corporation, Dompe Farmaceutici S.p.A., Lee’s Pharmaceutical Holdings Limited, Peregrine Pharmaceuticals, Inc., RegeneRx Biopharmaceuticals, Inc., Sirnaomics, Inc., The Medicines Company.
Drugs profiles discussed in this report includes brilacidin tetrahydrochloride, C-31G, dipyridamole, IBN-1, LQ-7, moxifloxacin hydrochloride, PGN-632, PIM-45, Recombinant Human Nerve Growth Factor, RGN-259, Small Molecules to Inhibit ATM for Herpes Keratitis, STP-601, targocil, tigecycline. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388754. (This is a premium report priced at US$2000 for a single user License.)
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Featured News & Press Releases cover by this report includes: Oct 20, 2014: RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy; Jul 23, 2014: Dompe announces the Food and Drug Administration has granted orphan drug designation to its rhNGF-based treatment for neurotrophic keratitis; Nov 04, 2013: Cellceutix to Pursue Significant Conjuctivitis and Kerititis Ocular Markets With Novel Antibiotic Brilacidin; Feb 14, 2013: Dompe Announces Enrollment Of First Patient In First International Clinical Trial Of rhNGF For Treatment Of Neurotrophic Keratitis.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Reasons to buy
-- Provides strategically significant competitor information, analysis, and
insights to formulate effective R&D development strategies
-- Identify emerging players with potentially strong product portfolio and
create effective counter-strategies to gain competitive advantage
-- Develop strategic initiatives by understanding the focus areas of
leading companies
-- Identify and understand important and diverse types of therapeutics
under development for Keratitis
-- Plan mergers and acquisitions effectively by identifying key players of
the most promising pipeline
-- Devise corrective measures for pipeline projects by understanding
Keratitis pipeline depth and focus of Indication therapeutics
-- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-- Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Explore more reports on Ophthalmology Therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/ophthalmology-therapeutics.
More reports on Pipeline Therapeutics Review 2015:
Peanut Allergy – Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Peanut Allergy. The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. Companies discussed in this report include BioTech Tools s.a., DBV Technologies S.A.., HAL Allergy BV, Immunomic Therapeutics, Inc.
Febrile Neutropenia – Pipeline Review, H1 2015
This report provides a review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sourcesCompanies discussed in this report include Apotex, Inc., Biocon Limited, Coherus BioSciences, Inc., Pfizer Inc., Richter Gedeon Nyrt., Sandoz International GmbH, Teva Pharmaceutical Industries Limited, Therapeutic Proteins International, LLC, Xenetic Biosciences plc.
Treatment Resistant Depression – Pipeline Review, H1 2015
The report reviews key players involved in the therapeutics development for Treatment Resistant Depression and enlists all their major and minor projects. Coverage of the Treatment Resistant Depression pipeline on the basis of target, MoA, route of administration and molecule type. Companies discussed in this report include Addex Therapeutics Ltd, Amorsa Therapeutics Inc., Edgemont Pharmaceuticals, LLC, F. Hoffmann-La Roche Ltd., Johnson & Johnson, MarcoPolo Pharmaceuticals SA, Otsuka Holdings Co., Ltd.
About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers. Call +1 888 391 5441 with your research requirements or email the details on [email protected] This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need.
Media Contact: Ritesh Tiwari, RnR Market Research, +1888391544, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE RnR Market Research
Comments